Yearly infusion with zoledronic acid (ZOL) has previously been shown to reduce fractures in women with postmenopausal osteoporosis. However, bisphosphonates have a long skeletal half-life and there are potential risks associated with prolonged use, including atypical fractures and osteonecrosis of the jaw; the ideal duration of therapy is not clearly defined.
This multicentre randomized double-blinded placebo-controlled extension study involved 1233 postmenopausal women with osteoporosis who, in a previous study, had received three annual infusions of ZOL. They were randomized to receive a further three annual infusions of ZOL or placebo. Risks of non-vertebral fracture and vertebral fracture were the main outcomes. Of note, this study was originally powered to examine changes in bone mineral density (BMD) rather than fractures; the fracture numbers recorded were small.
Discontinuation of ZOL was associated with low fracture risk in the ensuing 3 years in participants with a hip BMD above the osteoporotic range, who had not fractured during initial therapy and had 41 other risk factor (prevalent pre-trial vertebral fracture or femoral neck BMD 4-2.5). The authors conclude that in this low risk population temporary cessation of ZOL may be reasonable. Anti-Mu¨llerian hormone (AMH) is expressed in developing ovarian follicles. Levels correlate with antral follicle count and thus are higher in polycystic ovarian syndrome (PCOS). The main aim of this study was to evaluate whether AMH measured at age 16 years could predict a future diagnosis of PCOS. AMH, testosterone (T) and metabolic markers were determined in 400 Northern Finland Birth Cohort 1986 patients at age 16 years. Subjects were then stratified into quartiles of serum T. Questionnaires at 16 and 26 years collected data on signs/symptoms, or a formal diagnosis of PCOS.
At 16 years, AMH correlated positively with T, with significance at the highest T quartile only. Girls with oligo-or amenorrhoea had significantly higher AMH than those reporting normal cycles. Women with PCOS at 26 years had significantly higher AMH levels at 16 years. At an AMH cut-off of 22.5 pmol/L, sensitivity for predicting PCOS was 85.7%; however specificity was 37.5%. There were no significant associations between AMH and metabolic parameters or degree of hirsutism.
This study shows that although increased AMH levels measured in adolescence are associated with hyperandrogenism and/or oligo-or amenorrhoea, it is not useful for predicting a future diagnosis of PCOS. 
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